ID   CUTO-42
AC   CVCL_C5VT
SY   CUTO42; Colorado University Thoracic Oncology 42
DR   Wikidata; Q116048815
RX   PubMed=33795352;
CC   Sequence variation: Gene fusion; HGNC; HGNC:1316; EML4 + HGNC; HGNC:9967; RET; Name(s)=EML4-RET; Note=EML4 exon 9 fused to RET exon 12 (PubMed=33795352).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 5
//
RX   PubMed=33795352; DOI=10.1124/molpharm.120.000207; PMCID=PMC11033948;
RA   Schubert L., Le A.T., Estrada-Bernal A., Doak A.E., Yoo M.,
RA   Ferrara S.E., Goodspeed A., Kinose F., Rix U., Tan A.-C.,
RA   Doebele R.C.;
RT   "Novel human-derived RET fusion NSCLC cell lines have heterogeneous
RT   responses to RET inhibitors and differential regulation of downstream
RT   signaling.";
RL   Mol. Pharmacol. 99:435-447(2021).
//